endosialin-directed chimeric antigen receptor T cells

Endosialin-directed chimeric antigen receptor T cells (specifically the E3K CAR-T construct) are an experimental cell-based immunotherapy designed to treat solid tumors by targeting the tumor microenvironment. These T cells are genetically engineered to express a chimeric antigen receptor (CAR) that recognizes endosialin (also known as CD248 or Tumor Endothelial Marker 1 [TEM1]), a cell surface glycoprotein highly expressed on tumor-associated pericytes and perivascular cancer-associated fibroblasts (CAFs). Unlike conventional CAR-T therapies that target antigens on tumor cells, this approach targets the supportive stroma and vasculature of the tumor. By eliminating these cells, the therapy aims to disrupt the immunosuppressive environment and the blood supply of the tumor, thereby inhibiting tumor growth and enhancing the infiltration of other immune cells. Preclinical studies have shown efficacy in models of breast cancer, lung cancer, and triple-negative breast cancer, demonstrating the ability to recognize both human and murine endosialin.

Other names

CD248-directed CAR-T cellsCD-248-directed CAR-T cellsCD 248-directed CAR-T cellsTEM1-directed CAR-T cellsTEM-1-directed CAR-T cellsTEM 1-directed CAR-T cellsanti-endosialin CAR-T cellsendosialin-targeted CAR-T cells